ViroMed Preps US Trial For First Diabetic Ulcer Gene Therapy
This article was originally published in PharmAsia News
Executive Summary
After receiving US FDA approval to start a Phase III clinical trial with its gene therapy for diabetic peripheral neuropathy earlier this year, South Korea’s ViroMed is set for another Phase III study in the US, this time for a chronic non-healing ischemic diabetic foot ulcer therapy, which is the first gene therapy to be developed for this indication and which the firm is looking to partner.